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Introduction
The pathogenesis of premature luteinization in con-
trolled ovarian hyperstimulation (COH) is still poorly
understood. The role of elevated serum progesterone
(P) in the late follicular phase of COH is still contro-
versial. Elevated serum P has been reported with a
wide clinical spectrum of ovarian response or in vitro
fertilization (IVF) and clinical outcomes [1–5]. One of
the major reasons for the controversy has been the
diverse definitions of premature luteinization in previ-
ous literature. Most studies considered the occurrence
of premature luteinization when serum P exceeded a
certain level, in a range from 0.8 to 2 ng/mL [4,6–11].
Furthermore, it has been asserted that ovarian response
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SUMMARY
Objective: We investigated the influence of premature luteinization in in vitro fertilization using a long protocol
of gonadotropin-releasing hormone agonist (GnRHa) and recombinant follicle-stimulating hormone (rFSH),
taking ovarian response into account in the definition of premature luteinization.
Materials and Methods: A total of 339 cycles of controlled ovarian hyperstimulation with rFSH and GnRHa
were performed in 311 infertile couples. Premature luteinization was defined as a progesterone (P) to estradiol
(E2) ratio of > 1 on the day of human chorionic gonadotropin (hCG) administration. The P/E2 ratio is calcu-
lated as: P (ng/mL) × 1,000/E2 (pg/mL). Clinical outcomes were compared for the prematurely luteinized and
non-prematurely luteinized groups.
Results: The mean number of retrieved oocytes, recovered mature oocytes, embryos and top quality embryos
were significantly higher in the non-prematurely luteinized group than in the prematurely luteinized group.
Although fertilization rates and implantation rates were similar between the two groups, the clinical pregnancy
rate was higher in the non-prematurely luteinized group than in the prematurely luteinized group.
Conclusion: Premature luteinization, defined as late follicular P/E2 ratio of > 1 in long GnRHa cycles with rFSH
stimulation, adversely affected ovarian responses and clinical outcomes. It seems unrelated to preovulatory
luteinizing hormone (LH) elevation and LH/hCG content of gonadotropins and could be associated with poor
ovarian response and the presence of dysmature follicles. [Taiwan J Obstet Gynecol 2008;47(2):168–174]
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or reserve may be of critical importance when consid-
ering premature luteinization [2]. More follicles pro-
duce more serum P. It would, therefore, be better to
take into account the ovarian response, rather than the
serum P level only, when considering the reasons for
premature luteinization. Therefore, using the definition
of P to estradiol (E2) ratio of > 1 for premature luteiniza-
tion, rather than the P concentration only, may make it
possible to differentiate increased late follicular P levels
due to multiple follicular secretion in women with good
ovarian response from high P levels resulting from P
secretion due to premature luteinization. Younis et al [2]
defined premature luteinization as a P/E2 ratio of >1
on the day of human chorionic gonadotropin (hCG)
administration. Their work suggests that premature
luteinization in long gonadotropin-releasing hormone
agonist (GnRHa) cycles with human menopausal
gonadotropin (hMG) stimulation seems to adversely
affect clinical outcomes.
Some investigators believed that premature luteiniza-
tion is associated with elevation of follicular luteinizing
hormone (LH) levels [12]. Since the introduction of
long GnRHa protocol, pituitary desensitization has
usually been profound and endogenous LH levels 
have usually been low. Other investigators have sug-
gested that the serum accumulation of hCG from
hMG is responsible for premature luteinization [13].
Therefore, the use of recombinant follicle-stimulating
hormone (rFSH) instead of hMG has been regarded as
an excellent model for elucidating this phenomenon.
Ubaldi et al [4] analyzed the IVF and clinical outcomes
of women who underwent COH by using GnRHa in
combination with rFSH or urinary follicle-stimulating
hormone (FSH). They found that greater FSH expo-
sure correlated with P exposure and suggested that 
the cause of the subtle rise in P may be related to 
an increased LH sensitivity of the granulosa cells of
FSH-treated cycles. However, they defined premature
luteinization by serum P level only. Furthermore,
Adonakis et al [14] suggested that an increase in 
P in the late follicular phase is unrelated to any luteiniz-
ing process attributable to effects of follicular cells 
to LH.
If increased P/E2 ratio in the late follicular phase
could adversely alter the clinical outcomes of COH
induced by a long protocol of GnRHa and hMG, this
may also be true in long GnRHa cycles with rFSH
administration. In this study, we sought to quantify the
incidence of premature luteinization during GnRHa-
assisted reproduction cycles with rFSH stimulation and
to determine whether this premature increase in P/E2
ratio is associated with adverse outcomes in terms of
pregnancy and implantation.
Materials and Methods
An institutional review board approved the chart
review of 311 infertile couples who underwent 339
cycles of COH with rFSH and GnRHa in our assisted
reproductive technology program. The women were
aged 20–40 years, and the main indications for IVF
included male factors, tubal factors, unexplained infer-
tility, and endometriosis. Patients with short protocols,
dual suppression protocols, oocyte donation, and cycles
incorporating hMG were excluded.
Ovarian stimulation was performed as previously
described [15]. Briefly, all patients underwent a long
stimulation protocol of GnRHa therapy followed by
rFSH administration and transvaginal oocyte retrieval.
Once adequate follicular maturation had been ob-
tained, hCG (10,000 IU; Pregnyl; N.V. Organon, The
Netherlands) was administered and oocyte retrieval was
performed 35 to 37 hours later by transvaginal aspira-
tion with ultrasound guidance. Follicular fluids and
follicular washes were examined microscopically with
a dissecting stereomicroscope situated inside an incu-
bator with a controlled, humidified atmosphere of 37°C
and 5% CO2. The sperm insemination procedure in IVF
cycles was performed according to our routine protocol.
In brief, the oocyte–corona–cumulus complexes were
cultured in IVF medium (Medicult, Denmark) 4–6 hours
after retrieval in four-well multidishes (Nunc, Roskilde,
Denmark) before insemination. Following the incuba-
tion, oocytes were inseminated with spermatozoa to a
concentration of ~105 motile spermatozoa/mL in 1 mL
of IVF medium. Then, oocytes were withdrawn from the
insemination medium after a 2-hour exposure to sper-
matozoa. Each oocyte was cultured in fresh IVF medium
in the four-well culture dish again. In the intracytoplas-
mic sperm injection (ICSI) program, the oocytes were
exposed to 80 IU/mL of hyaluronidase (type VIII; Sigma
Chemical Co., St Louis, MO, USA) for 5 to 6 seconds.
The surrounding cumulus cells were stripped from
oocytes by aspirating through a series of pipettes with
decreasing inner diameters (220, 200, 180, and 160 µm)
in 100-µL droplets of human tubal fluid medium. The
sperm injection procedure in the ICSI cycle was based
on a modified protocol as previously described [16].
After completion of the ICSI or IVF procedures, the
oocytes were cultured according to our standardized 
in vitro culture procedure [17]. They were assessed for the
presence of pronuclei after 16–18 hours of incubation.
Fertilization was considered to have occurred when two
clear pronuclei were present. If only one pronucleus was
observed, a second evaluation was performed 4 hours
later to determine whether the pronuclear status had
changed. The developmental competence of zygotes with
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two pronuclei was evaluated after a further 96 hours of
in vitro culture. Embryos were cultured in a similar fashion
to the standard protocol with the primary exception of
the type of media and the duration of culture. Briefly, the
embryos were placed in G1.2 medium (Scandinavian
IVF Science, Gothenburg, Sweden) on day 1 post-
fertilization, followed by G2.2 medium (Scandinavian
IVF Science, Gothenburg, Sweden) on days 3–6. The
cleaved embryos were classified according to the mor-
phologic grading system described by Veeck [18]. The
blastocysts were assigned a score according to the sys-
tem of Gardner et al [19]. Grade I/II day-3 and day-8 cell
embryos were defined as top-quality embryos (TQEs)
[20]. Top-scoring blastocysts (TQEs) were defined as
blastocysts with scores of 3AA, 4AA or 5AA [21].
Statistical analysis
Premature luteinization was defined as a P/E2 ratio of
> 1, and the ratio calculation was performed as follows:
P (ng/mL) × 1,000/E2 (pg/mL). The prematurely lutein-
ized and non-prematurely luteinized groups were com-
pared with respect to age, levels of LH, P, and E2, dose
of rFSH, duration of stimulation, number of oocytes
retrieved, number of embryos and TQEs, implantation
rate, and pregnancy rate.
Data were analyzed using SPSS version 9.0 (SPSS
Inc., Chicago, IL, USA). The unpaired Student’s t test,
Mann-Whitney rank sum test or Fisher’s exact test
were used for statistical analyses as appropriate. The
significance level was set at p < 0.05.
Results
According to the criterion of P/E2 ratio of > 1, 137 of
339 cycles were demonstrated to have premature
luteinization in the study group (Tables 1 and 2). The
incidence of premature luteinization was 40.4%. Ovarian
responses were demonstrated as poor with serum
estradiol levels of < 500 pg/mL on hCG administra-
tion day. It was noted that there were more cases with
poor ovarian response in the study group (Table 3).
The mean age was similar between the group with
and the group without premature luteinization (Table
1). The level of P on the day of hCG administration was
higher (1.3 ± 1.0 vs. 1.1 ± 0.5 ng/mL; p < 0.05) and the
peak estradiol was lower (804.1 ± 495.9 vs. 1,827.9 ±
906.1 pg/mL; p < 0.05) in the study group. The mean
level of LH on day 6 of stimulation was similar in both
the control and study groups (1.4 ± 1.2 vs. 1.4 ±
0.9 mIU/mL; p = 0.641), but higher in the control group
than in the study group on the day of hCG administra-
tion (1.5 ± 1.1 vs. 1.0 ± 0.6 mIU/mL; p < 0.05).
The number of oocytes retrieved (7.9 ± 3.9 vs. 4.7 ±
2.9; p < 0.05) and mature oocytes recovered (4.6 ± 2.4
vs. 2.8 ± 1.8; p < 0.05) were significantly higher in the
control group than in the study group (Table 1). Fertil-
ization rates were similar between the two groups.
Regarding embryo development, embryo number (6.5 ±
3.6 vs. 3.9 ± 2.6; p < 0.05), TQE number (4.4 ± 2.7 vs.
2.8 ± 1.9; p < 0.05), transferred embryo number (2.9 ±
0.8 vs. 2.5 ± 1.1; p < 0.05) and transferred TQE num-
ber (2.5 ± 1.0 vs. 2.2 ± 1.2; p < 0.05) were significantly
higher for the control group than the study group
(Table 2). However, the percentage of TQE was similar
for the control and study groups (67.5% vs. 71.7%;
p = 0.127).
The number of days of stimulation did not differ
significantly, but the total number of ampoules of
rFSH used was lower in the control group than in the
study group (28.7 ± 8.3 vs. 32.2 ± 12.2; p < 0.05).
All patients in both groups received embryo transfers.
Table 1. Ovarian response of controlled ovarian hyperstimulation cycles (n = 339) in the study and control groups*
Control group (n = 202)† Study group (n = 137)† p
Age (yr) 32.3 ± 4.1 32.8 ± 3.6 0.392
Hormone levels
LH on day 6 (mIU/mL) 1.4 ± 1.2 1.4 ± 0.9 0.641
LH on hCG day (mIU/mL) 1.5 ± 1.1 1.0 ± 0.6 < 0.05
Progesterone (ng/mL) 1.1 ± 0.5 1.3 ± 1.0 < 0.05
Estradiol (pg/mL) 1,827.9 ± 906.1 804.1 ± 495.9 < 0.05
Oocytes
Oocyte (n) 7.9 ± 3.9 4.7 ± 2.9 < 0.05
Mature oocyte (n) 4.6 ± 2.4 2.8 ± 1.8 < 0.05
FSH dose (ampoule) 28.7 ± 8.3 32.2 ± 12.2 < 0.05
Duration of stimulation (d) 10.0 ± 1.9 10.4 ± 2.0 0.09
*Data are presented as mean ± standard deviation; †premature luteinization was defined according to the criterion, progesterone/E2 ratio > 1. LH = luteinizing
hormone; hCG = human chorionic gonadotropin; FSH = follicle-stimulating hormone.
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One hundred and thirty gestational sacs were demon-
strated by ultrasonography after the transfer of 577
embryos in the control group, and 76 gestational sacs
were noted after the transfer of 339 embryos in the
study group. Procedures for the non-prematurely
luteinized group yielded a similar implantation rate as
those for the prematurely luteinized group (22.5% vs.
22.4%; p = 1.0). Furthermore, 98 (48.5%) clinical preg-
nancies were achieved in the 202 cycles without pre-
mature luteinization. In contrast, 50 (36.5%) pregnancies
were achieved in 137 cycles with premature luteinization.
The difference was statistically significant (p < 0.05).
Discussion
It has been debated for many years whether P increase
in the late follicular phase of COH has a detrimental
effect on the outcome of IVF. Reduced implantation
and pregnancy rates were reported by some but not all
investigators. The definition of premature luteiniza-
tion differed and was believed to be responsible for the
variable pregnancy rates in previously published litera-
ture. Most studies used an absolute P level on the day
of hCG administration as an indicator of premature
luteinization, and the cutoff level differed from 0.8 to
2 ng/mL [4,6–11]. Recently, Younis et al [12] defined
premature luteinization as a P/E2 ratio of > 1. This cri-
terion could differentiate between the P level secretion
from dysmature follicles and physiologic secretion from
multiple healthy mature follicles. Based on this defini-
tion, they concluded that premature luteinization
adversely affected clinical outcomes in long GnRHa
cycles with hMG stimulation. Previous literature reported
incidence of premature luteinization varying from 13%
to 71%, using P only to define premature luteinization
[4–10]. The incidence of premature luteinization in the
present study was 40.41%, which is similar to 41% in
the report of Younis et al [2], using the definition of P/E2
ratio > 1 for premature luteinization. Thus, it is sug-
gested that the main reason for the variation was the
use of different definitions for premature luteinization.
Premature luteinization as defined by the P/E2
ratio was more prevalent in poor ovarian responders in
our study (Table 3). Perhaps it related to poor ovarian
response with increased LH sensitivity, similar to the
report by Younis et al [2]. This assumption deserves fur-
ther evaluation. Premature luteinization may adversely
affect the outcome of IVF by either altering oocyte
quality or impairing endometrial receptivity. Although
Table 2. Development potential of oocytes and clinical outcome in the study and control groups
Control group† Study group†
p
(n = 202 cycles) (n = 137 cycles)
Fertilization rate (%) 84.5 85.3 0.597
Embryos
Embryos (n)* 6.5 ± 3.6 3.9 ± 2.6 < 0.05
TQEs (n)* 4.4 ± 2.7 2.8 ± 1.9 < 0.05
TQE rate (%) 67.5 71.7 0.127
Transferred embryos, (n)* 2.9 ± 0.8 2.5 ± 1.1 < 0.05
Transferred TQEs (n)* 2.5 ± 1.0 2.2 ± 1.2 < 0.05
Endometrial thickness (cm)* 1.3 ± 0.3 1.2 ± 0.3 < 0.05
Implantation rate (%) 22.5 22.4 1.0
Pregnancy rate (%) 48.5 36.5 < 0.05
*Data are presented as mean ± standard deviation; †premature luteinization was defined according to the criterion, progesterone/E2 ratio > 1. TQE = top-quality
embryo.
Table 3. Patient distribution according to peak estradiol (E2) level*
Peak E2 level (pg/mL)
Control group† Study group†
p
(n = 202 cycles) (n = 137 cycles)
< 500 3 (1.5) 34 (24.8) < 0.001
500–1,000 32 (15.8) 72 (52.6) < 0.001
1,000–2,000 101 (50) 27 (19.7) < 0.001
> 2,000 66 (32.7) 4 (2.9) < 0.001
*Data are presented as n (%); †premature luteinization was defined according to the criterion, progesterone/E2 ratio > 1.
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several studies suggested that the lower pregnancy rate
in premature luteinization was associated with reduced
oocyte or embryo quality, inappropriate definitions of
premature luteinization mean that this needs to be fur-
ther evaluated [11,22]. In the present study, there were
significantly lower numbers of both total oocytes and
matured oocytes retrieved in the prematurely luteinized
group than in the non-prematurely luteinized group.
Younis et al [2] found that premature luteinization in
patients with unexplained infertility was related to a
lower number of follicles and indicated an early mani-
festation of low ovarian reserve. Low ovarian reserves
contribute to the process of follicular diminution,
often coupled with a decline in the number of oocytes
retrieved. On the contrary, Hofmann et al [9] reported
that higher serum P/E2 ratios on the day of hCG admin-
istration were not associated with diminished ovarian
reserves, as demonstrated by the clomiphene citrate
challenge test or pregnancy outcomes. They also found
a strong positive correlation between the P/E2 ratio and
the number of ampoules of hMG required for hyper-
stimulation, the peak estradiol level, and the number
of mature oocytes retrieved. However, we found that
the prematurely luteinized group required a higher
number of ampoules of rFSH for hyperstimulation, but
had lower peak estradiol levels and lower numbers of
oocytes retrieved than the non-prematurely luteinized
group. Our data were close to that of Younis et al [2].
The reasons for discrepancies between our results and
those of Hofmann et al [1] are not clear, since both
Younis et al [2] and Hofmann et al [1] used hMG for
stimulation, which contained LH, hCG and possible
growth factors. Özçakir et al [23] used rFSH for stimu-
lation and found that the prematurely luteinized group
had both a lower total number of oocytes and a lower
number of mature oocytes retrieved, the results of
which were similar to ours, except that they did not
record peak estradiol levels.
The pathogenesis of premature luteinization in long
GnRHa cycles is still controversial. Although pituitary
desensitization with GnRHa is reported to eliminate
both immunoactive and bioactive LH surges [24], 
a serum P rise during the late follicular phase can occur
when GnRHa is combined with gonadotropins for COH
in patients undergoing assisted reproductive techniques
[5–7,10,11]. Its incidence has been reported to occur
in 2–35% of cycles [4]. Although the long GnRHa pro-
tocol can prevent premature LH elevation in 95–98%
of patients [25,26], we cannot invariably blame
increased preovulatory LH levels as the sole patho-
genic factor in premature luteinization.
Is there any explanation for premature luteinization in
long GnRHa cycles with hMG stimulation? In comparing
women with and without premature luteinization dur-
ing GnRHa and hMG IVF cycles, Copperman et al [13]
found higher hCG serum levels in women who experi-
enced a serum P rise, suggesting that premature lutein-
ization, despite pituitary suppression with GnRHa, may
be due to the hCG content of hMG [27]. According 
to this hypothesis, the use of human rFSH or human
urinary FSH in which LH activity is negligible [28] or
practically absent [29] should not provoke premature
luteinization. If this was the unique etiology of prema-
ture luteinization, the use of rFSH with negligible
intrinsic LH bioactivity should then help avoid prema-
ture P rise. However, in the present study, we observed
the occurrence of premature luteinization in patients
who underwent COH by using GnRHa in combination
with rFSH for assisted reproductive technology, as in
the previous reports [4,23]. Some authors have pro-
posed that the urinary hCG or LH content of the
menotropins causes subtle elevations in P levels
[5,13]. However, we as well as others [4,23] have used
rFSH exclusively and have found a high incidence of
P/E2 ratio elevation, even though follicles were not
exposed to these putative contaminants. Based on LH
measurements and the use of rFSH, we can safely con-
clude that neither the LH nor the hCG content of the
recombinant preparations is responsible for this eleva-
tion of P/E2 ratio level.
It seems that there may be another mechanism to
explain the premature luteinization in long GnRHa
cycles with rFSH stimulation. Younis et al [2] suggested
that premature luteinization is not necessarily an LH-
dependent event and may be primarily related to an
adversely affected cumulus–oocyte complex. Their LH
levels on the day of hCG administration were similar
for the study and control groups. In our study, the lev-
els of LH on day 6 of ovarian stimulation were similar
in both groups and, more interestingly, higher in the
non-prematurely luteinized group than the prema-
turely luteinized group on the day of hCG administra-
tion (1.5 ± 1.1 vs. 1.0 ± 0.6 mIU/mL). As stated above,
speculation has been that premature luteinization may
be related to poor ovarian response with increased LH
sensitivity [2]. Using rFSH instead of hMG could elimi-
nate exogenous LH, hCG and growth factors in the
preparation of gonadotropins, and permit a more ele-
gant examination of the phenomenon of premature
luteinization. Although the actions of FSH have been
exhaustively studied and are thought to be well defined,
there have been some novel twists to the FSH signal trans-
duction. In particular, FSH stimulates the phosphory-
lation of kinases closely related to protein kinase A that
are downstream targets of insulinlike growth factor-1
[30–32]. Thus, hyperstimulation with FSH may induce
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the expression of genes other than only the aromatase
pathway. These findings are consistent with those
recently reported by Filicori et al [33], who found a
strong positive correlation between the administered
dose of FSH and follicular phase P levels.
In conclusion, the present study shows that prema-
ture luteinization, defined as late follicular P/E2 ratio
of > 1 in long GnRHa cycles with rFSH stimulation,
adversely affected ovarian responses and clinical out-
comes. It apparently does not seem to be linked to the
preovulatory LH elevation and LH/hCG content of
gonadotropins. It could be associated with poor ovar-
ian response and the presence of dysmature follicles.
However, longer series are needed to better address
this issue.
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